全文获取类型
收费全文 | 2600篇 |
免费 | 393篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 70篇 |
妇产科学 | 296篇 |
基础医学 | 183篇 |
口腔科学 | 108篇 |
临床医学 | 892篇 |
内科学 | 370篇 |
皮肤病学 | 55篇 |
神经病学 | 43篇 |
特种医学 | 247篇 |
外科学 | 116篇 |
综合类 | 155篇 |
一般理论 | 1篇 |
预防医学 | 155篇 |
眼科学 | 15篇 |
药学 | 145篇 |
肿瘤学 | 135篇 |
出版年
2023年 | 44篇 |
2021年 | 13篇 |
2020年 | 40篇 |
2019年 | 25篇 |
2018年 | 69篇 |
2017年 | 98篇 |
2016年 | 83篇 |
2015年 | 111篇 |
2014年 | 118篇 |
2013年 | 128篇 |
2012年 | 104篇 |
2011年 | 159篇 |
2010年 | 118篇 |
2009年 | 119篇 |
2008年 | 83篇 |
2007年 | 99篇 |
2006年 | 76篇 |
2005年 | 55篇 |
2004年 | 39篇 |
2003年 | 38篇 |
2002年 | 56篇 |
2001年 | 65篇 |
2000年 | 25篇 |
1999年 | 63篇 |
1998年 | 105篇 |
1997年 | 114篇 |
1996年 | 114篇 |
1995年 | 100篇 |
1994年 | 72篇 |
1993年 | 56篇 |
1992年 | 50篇 |
1991年 | 40篇 |
1990年 | 27篇 |
1989年 | 47篇 |
1988年 | 45篇 |
1987年 | 30篇 |
1986年 | 36篇 |
1985年 | 53篇 |
1984年 | 24篇 |
1983年 | 22篇 |
1982年 | 29篇 |
1981年 | 19篇 |
1980年 | 20篇 |
1979年 | 14篇 |
1978年 | 19篇 |
1977年 | 22篇 |
1976年 | 24篇 |
1975年 | 25篇 |
1973年 | 11篇 |
1972年 | 10篇 |
排序方式: 共有3001条查询结果,搜索用时 531 毫秒
81.
Dziennis S; Van Etten RA; Pahl HL; Morris DL; Rothstein TL; Blosch CM; Perlmutter RM; Tenen DG 《Blood》1995,85(2):319-329
CD11b is the alpha chain of the Mac-1 integrin and is preferentially expressed in myeloid cells (neutrophils, monocytes, and macrophages). We have previously shown that the CD11b promoter directs cell-type- specific expression in myeloid lines using transient transfection assays. To confirm that these promoter sequences contain the proper regulatory elements for correct myeloid expression of CD11b in vivo, we have used the -1.7-kb human CD11b promoter to direct reporter gene expression in transgenic mice. Stable founder lines were generated with two different reporter genes, a Thy 1.1 surface marker and the Escherichia coli lacZ (beta-galactosidase) gene. Analysis of founders generated with each reporter demonstrated that the CD11b promoter was capable of driving high levels of transgene expression in murine macrophages for the lifetime of the animals. Similar to the endogenous gene, transgene expression was preferentially found in mature monocytes, macrophages, and neutrophils and not in myeloid precursors. These experiments indicate that the -1.7 CD11b promoter contains the regulatory elements sufficient for high-level macrophage expression. This promoter should be useful for targeting heterologous gene expression to mature myeloid cells. 相似文献
82.
Lord BI; Woolford LB; Wood LM; Czaplewski LG; McCourt M; Hunter MG; Edwards RM 《Blood》1995,85(12):3412-3415
BB-10010 is a genetically engineered variant of human macrophage inflammatory protein-1 alpha with improved solution properties. We show here that it mobilizes stem cells into the peripheral blood. We investigated the mobilizing effects of BB-10010 on the numbers of circulating 8-day spleen colony-forming units (CFU-S8), CFU-S12, and progenitors with marrow repopulating ability (MRA). A single subcutaneous dose of BB-10010 caused a twofold increase in circulating numbers of CFU-S8, CFU-S12, and MRA 30 minutes after dosing. We also investigated the effects of granulocyte colony-stimulating factor (G- CSF) and the combination of G-CSF with BB-10010 on progenitor mobilization. Two days of G-CSF treatment increased circulating CFU-S8, CFU-S12, and MRA progenitors by 25.7-, 19.8-, and 27.7-fold. A single administration of BB-10010 after 2 days of G-CSF treatment increased circulating CFU-S8, CFU-S12, and MRA even further to 38-, 33-, and 100- fold. Splenectomy resulted in increased circulating progenitor numbers but did not change the pattern of mobilization. Two days of treatment with G-CSF then increased circulating CFU-S8, CFU-S12, and MRA by 64-, 69-, and 32-fold. A single BB-10010 administration after G-CSF treatment further increased them to 85-, 117-, and 140-fold, respectively, compared with control. We conclude that BB-10010 causes a rapid increase in the number of circulating hematopoietic progenitors and further enhances the numbers induced by pretreatment with G-CSF. BB- 10010 preferentially mobilized the more primitive progenitors with marrow repopulating activity, releasing four times the number achieved with G-CSF alone. Translated into a clinical setting, this improvement in progenitor cell mobilization may enhance the efficiency of harvest and the quality of grafts for peripheral blood stem cell transplantation. 相似文献
83.
Previous studies have shown that inhibition of the lipoxygenase pathway of arachidonic acid metabolism can prevent the development of elevated blood pressure in renin-dependent models of hypertension. Agents that inhibit the lipoxygenase pathway such as phenidone and the flavonoid baicalein can selectively attenuate contractile responses to angiotensin II in vivo as well as in isolated vascular tissue. In the present study, the effects of lipoxygenase inhibitors on pressor-induced changes in cytosolic calcium were examined in cultured rat vascular smooth muscle cells using the fluorescent dye fura-2. Two structurally unrelated lipoxygenase inhibitors, baicalein and 5,8,11-eicosatriynoic acid, attenuated angiotensin II-stimulated increases in cytosolic calcium in both normal and calcium-poor buffer. The addition of 5-, 12-, or 15(S)-hydroxyeicosatetraenoic acid alone to the cells had no acute effect on intracellular calcium concentration. However, the addition of 12(S)-hydroxyeicosatetraenoic acid but not 5- or 15(S)-hydroxyeicosatetraenoic acid restored the initial calcium response to angiotensin II in vascular smooth muscle cells pretreated with both inhibitors; 5,8,11-eicosatriynoic acid also reduced [Arg8]-vasopressin and endothelin-stimulated increases in intracellular calcium. The attenuation of vasopressor-induced calcium transients by agents that inhibit lipoxygenase may explain their observed hypotensive effects in vivo. Moreover, lipoxygenase products, in particular 12(S)-hydroxyeicosatetraenoic acid, may act as mediators for the intracellular actions of angiotensin II and possibly other pressor hormones in vascular tissue by regulation of intracellular calcium metabolism. 相似文献
84.
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations 总被引:1,自引:0,他引:1
Li Z Lu J Sun M Mi S Zhang H Luo RT Chen P Wang Y Yan M Qian Z Neilly MB Jin J Zhang Y Bohlander SK Zhang DE Larson RA Le Beau MM Thirman MJ Golub TR Rowley JD Chen J 《Proceedings of the National Academy of Sciences of the United States of America》2008,105(40):15535-15540
MicroRNAs (miRNAs) are postulated to be important regulators in cancers. Here, we report a genome-wide miRNA expression analysis in 52 acute myeloid leukemia (AML) samples with common translocations, including t(8;21)/AML1(RUNX1)-ETO(RUNX1T1), inv(16)/CBFB-MYH11, t(15;17)/PML-RARA, and MLL rearrangements. Distinct miRNA expression patterns were observed for t(15;17), MLL rearrangements, and core-binding factor (CBF) AMLs including both t(8;21) and inv(16) samples. Expression signatures of a minimum of two (i.e., miR-126/126*), three (i.e., miR-224, miR-368, and miR-382), and seven (miR-17-5p and miR-20a, plus the aforementioned five) miRNAs could accurately discriminate CBF, t(15;17), and MLL-rearrangement AMLs, respectively, from each other. We further showed that the elevated expression of miR-126/126* in CBF AMLs was associated with promoter demethylation but not with amplification or mutation of the genomic locus. Our gain- and loss-of-function experiments showed that miR-126/126* inhibited apoptosis and increased the viability of AML cells and enhanced the colony-forming ability of mouse normal bone marrow progenitor cells alone and particularly, in cooperation with AML1-ETO, likely through targeting Polo-like kinase 2 (PLK2), a tumor suppressor. Our results demonstrate that specific alterations in miRNA expression distinguish AMLs with common translocations and imply that the deregulation of specific miRNAs may play a role in the development of leukemia with these associated genetic rearrangements. 相似文献
85.
Harriet Chan-Myers BS RM David McAlister PhD ABMM Patricia Antonoplos PhD 《American journal of infection control》1997,25(6):471-476
Controversy exists concerning the degree of microbial contamination associated with the us of rigid lumened medical devices, the efficacy of standard cleaning techniques used to remove pathogenic microorganisms from lumen channels, and whether patients are placed at risk of cross infection because of microbial contamination. In this study the level and types of microorganisms found on rigid lumened medical devices before and after cleaning in a hospital environment were investigated. The bioburden level after clinical use was found to be relatively low, ranging from 101 to 104 colony forming units (CFU) per device. After the instruments were cleaned, none of the devices studied contained bioburden levels greater than 104 CFU and 83% had bioburden levels less than or equal to 102 CFU. The bioburden present before cleaning was comprised of organisms derived from the handling of the device, from the hospital environment, and from the patient. The bioburden present after cleaning was comprised of organisms typically derived from the handling of the device and from the hospital environment. The level of bioburden per device was also related to the anatomic site where the device was used, with lower numbers of organisms found on devices exposed to sterile body sites and the respiratory tract. 相似文献
86.
Although the proto-oncogene rhombotin-2 (RBTN-2) is widely expressed in most tissues, it is not expressed in T cells. We investigated the potential for overexpression of RBTN-2 to cause tumors in T cells and other tissues by constructing transgenic mice that expressed RBTN-2 under control of the metallothionein-1 promoter. Despite overexpression of RBTN-2 in all tissues, transgenic mice developed T-cell tumors only, thus indicating that tumorigenesis caused by RBTN-2 is T-cell-specific. Thymic tumors were found between 37 and 71 weeks and were invariably associated with metastasis to nonlymphoid organs. Thymuses from apparently healthy transgenic mice were also examined. In some mice there was an 10-fold increase in the CD4-CD8- thymocyte subset, yet the total number of thymocytes was the same as that in wild-type mice. Thymic homeostasis was maintained by a compensatory reduction in the CD4+CD8+ subset. The expansion of CD4-CD8- thymocytes was associated with increased expression of RBTN-2 and with increased cell proliferation. No differences were found in the proportion of thymocytes undergoing apoptosis in transgenic mice. Furthermore, RBTN-2- induced expansion of CD4-CD8- cells did not block differentiation of these cells. Thymuses with 30% CD4-CD8- cells were essentially monoclonal, indicating that all thymic immunophenotypes were derived from a single clone. Overall, our data are consistent with the following scenario: (1) RBTN-2 expression in T cells causes selective and polyclonal proliferation of CD4-CD8- thymocytes accompanied by a compensatory decrease in other thymocyte subsets; (2) a clone with growth advantage and differentiation potential is selected and populates the thymus; and (3) this clone eventually breaches homeostasis of the thymus, accompanied or followed by metastasis to other organs. 相似文献
87.
A feasibility study on using tablet personal computers for self‐reported symptom assessment in newly diagnosed lung cancer patients
下载免费PDF全文
![点击此处可从《International journal of nursing practice》网站下载免费的PDF全文](/ch/ext_images/free.gif)
88.
Understanding the experience of women admitted to a psychiatric hospital in Sydney with psychosis or mania following childbirth after World War II (1945–1955)
下载免费PDF全文
![点击此处可从《International journal of mental health nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
89.
90.